ClinicalTrials.gg
CompletedNCT06137482Updated Mar 19, 2025

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

A Phase 1 interventional study of REGN13335 and Matching Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults.

The aim of the study is to see how safe and tolerable REGN13335 is in healthy volunteers.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is present in the blood of study participants at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Has a between 18 and 32 kg/m\^2, inclusive, at the screening visit
  2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, laboratory safety tests, and (ECGs) performed prior to administration of study drug (ie, screening and baseline visit)

Key Exclusion Criteria:

  1. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    IV Cohort 1 Low Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    IV Cohort 2 Mid Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    IV Cohort 3 High Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    IV Cohort 4 Higher Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    IV Cohort 5 Highest Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    SC Cohort 1 Low Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    SC Cohort 2 High Dose

    Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

  • Experimental
    IV or SC Optional Cohort

    ≤ Highest IV or SC Dose as described in the protocol Randomized as described in the protocol

    Drug: REGN13335 · Drug: Matching Placebo

Interventions

  • DrugREGN13335

    Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose

  • DrugMatching Placebo

    Administered IV or SC, sequential ascending single dose

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAE's) through the end of the study (EOS) visit

    Time frame: Baseline to day 113

  2. Severity of TEAE's through the EOS visit

    Time frame: Baseline to day 113

Secondary outcomes

  1. Concentrations of functional REGN13335 in plasma through the EOS visit

    Time frame: Baseline to day 113

  2. Incidence of anti-drug antibodies (ADA) to single doses of REGN13335 over time

    Time frame: Baseline to day 113

  3. Titer of ADA to single doses of REGN13335 over time

    Time frame: Baseline to day 113

07

Study locations

1 site
  • New Zealand Clinical Research
    Christchurch, Canterbury 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Feb 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 18, 2023
StartActual
Dec 6, 2023
Primary completionActual
Feb 11, 2025
CompletionActual
Feb 11, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06137482
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 6, 2023
Primary completion
Feb 11, 2025
Completion
Feb 11, 2025
Last update
Mar 19, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion